Lin BioScience, Inc. (TPEX: 6696)
Health Care · Biotechnology · TW
NT$175.00
-3.58% today · +624.6% 1Y
Lin BioScience, Inc. (TPEX: 6696) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.54B and employs 20 people.
Over the last twelve months the share price has gained 624.6%, trading between 18.90 and 207.00.
Tweenvest scores Lin BioScience, Inc. across four factors: quality 41/100, value 88/100. Its strongest factor is value.
6696 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.54B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.94
- Dividend yield
- —
- Beta (5Y)
- -0.25
- 52-week high
- NT$207.00
- 52-week low
- NT$18.90
- Avg volume (3M)
- —
- Shares outstanding
- 829.20M
- Employees
- 20
- Next earnings
- —
About Lin BioScience, Inc.
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
- ISIN
- TW0006696008
- Listed since
- Oct 8, 2018
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Travere Therapeutics, Inc.NasdaqGM: TVTX | $4.91B | $52.44 | +0.60% |
| Chongqing Zhifei Biological Products Co., Ltd.SZSE: 300122 | $4.90B | CN¥13.70 | -2.00% |
| 3SBio Inc.SEHK: 1530 | $4.79B | HK$15.07 | +0.53% |
| Dianthus Therapeutics, Inc.NasdaqCM: DNTH | $4.61B | $82.17 | -0.24% |
| Shanghai Junshi Biosciences Co., Ltd.SEHK: 1877 | $4.45B | HK$17.65 | -2.32% |
| Imeik Technology Development Co.,Ltd.SZSE: 300896 | $4.28B | CN¥95.03 | -0.16% |
| Dizal (Jiangsu) Pharmaceutical Co., Ltd.SHSE: 688192 | $4.16B | CN¥59.95 | +3.34% |
| Suzhou Zelgen Biopharmaceuticals Co., Ltd.SHSE: 688266 | $4.12B | CN¥104.25 | -5.23% |
Figures last refreshed Oct 11, 2026.